{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-031309","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.530119+00:00","generated_at":"2026-05-15T09:34:26.770302+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"confidence":"high","headline":"Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL","bullets":["Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).","Cash $17M at Dec 31, 2025; expected to fund ops through Q4 2026 without new grants.","Phase 1 APOLLO data: 66% objective response rate in relapsed NHL, 50% complete responses.","MT-601 pancreatic cancer program to initiate in Q2 2026; Nature Medicine publication Jan 2026.","New board member Kathryn Penkus Corzo appointed Nov 2025; Cellipont manufacturing collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-031309","json":"https://secwatch.observer/filing/0001104659-26-031309.json","markdown":"https://secwatch.observer/filing/0001104659-26-031309.md","text":"https://secwatch.observer/filing/0001104659-26-031309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/0001104659-26-031309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:34:26.770302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}